Esperion's (ESPR) Drugs Get EU Nod for Lowering Heart Risk

Esperion Therapeutics, Inc. ESPR and partner Daiichi Sankyo Europe GmbH announced that the European Commission (EC) has approved a label update for its drugs Nilemdo (bempedoic acid) and Nustendi for the treatment of hypercholesterolemia and to reduce the risk of adverse cardiovascular (CV) events.

Yahoo FinanceMay 24 00:11

Esperion to Participate in Upcoming June Investor Conferences

ANN ARBOR, Mich., May 23, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the following webcasted investor events during the month of May,

GlobeNewswireMay 23 21:00

H.C. Wainwright Maintains Esperion Therapeutics(ESPR.US) With Buy Rating, Maintains Target Price $16

H.C. Wainwright analyst Joseph Pantginis maintains $Esperion Therapeutics(ESPR.US)$ with a buy rating, and maintains the target price at $16.According to TipRanks data, the analyst has a success rate

Futu NewsMay 23 17:34

Esperion Therapeutics Inc: European Commission Approves Labeling Updates for Nilemdo and Nustendi

Esperion Therapeutics Inc: European Commission Approves Labeling Updates for Nilemdo and Nustendi

Zhitong FinanceMay 22 20:03

Express News | Esperion Therapeutics Inc: European Commission Approved Label Update of Both Nilemdo and Nustendi

BreakingsMay 22 20:02

First-In-Class Cholesterol-Lowering Treatment NILEMDO (NEXLETOL in the U.S.) and Its Combination With Ezetimibe, NUSTENDI (NEXLIZET in the U.S.), Approved In Europe To Treat Hypercholesterolemia and Significantly Reduce Cardiovascular Risk

– NILEMDO (bempedoic acid), a First-In-Class, Oral Treatment and NUSTENDI (bempedoic Acid / Ezetimibe Fixed-Dose Combination) Receive Label Update Approval from The European Commission as Treatments t

GlobeNewswireMay 22 20:00